CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.867
EU - Europa 2.846
AS - Asia 2.214
SA - Sud America 282
AF - Africa 104
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.331
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.797
RU - Federazione Russa 1.261
SG - Singapore 884
CN - Cina 436
IT - Italia 385
GB - Regno Unito 249
HK - Hong Kong 235
BR - Brasile 232
DE - Germania 226
VN - Vietnam 189
FR - Francia 152
IE - Irlanda 151
FI - Finlandia 115
SE - Svezia 115
IN - India 91
KR - Corea 77
JP - Giappone 76
ID - Indonesia 46
ES - Italia 40
NL - Olanda 39
CA - Canada 36
SA - Arabia Saudita 32
TR - Turchia 27
TG - Togo 25
AR - Argentina 20
MX - Messico 20
UA - Ucraina 20
AT - Austria 19
BD - Bangladesh 19
BJ - Benin 19
IQ - Iraq 19
BE - Belgio 17
NG - Nigeria 16
ZA - Sudafrica 13
AU - Australia 11
PL - Polonia 11
EG - Egitto 10
PK - Pakistan 10
EC - Ecuador 8
IL - Israele 8
IR - Iran 8
HU - Ungheria 7
MY - Malesia 7
PH - Filippine 7
TW - Taiwan 6
AL - Albania 5
CL - Cile 5
GR - Grecia 5
KE - Kenya 5
MA - Marocco 5
UZ - Uzbekistan 5
BG - Bulgaria 4
CH - Svizzera 4
NZ - Nuova Zelanda 4
UY - Uruguay 4
VE - Venezuela 4
BH - Bahrain 3
CO - Colombia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
OM - Oman 3
TN - Tunisia 3
AG - Antigua e Barbuda 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
GT - Guatemala 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
ET - Etiopia 1
GF - Guiana Francese 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
Totale 8.324
Salva come PNG Salva come JPEG
Città #
Dallas 633
Singapore 448
Moscow 440
San Jose 381
Ashburn 369
Chandler 244
Hong Kong 227
Dublin 139
Verona 118
Munich 112
Beijing 99
The Dalles 89
Southend 87
New York 76
Ho Chi Minh City 73
Helsinki 69
Los Angeles 59
Council Bluffs 51
London 46
Jacksonville 43
Hanoi 37
Lawrence 34
Princeton 34
Milan 32
Paris 32
Lappeenranta 31
Jakarta 30
Redondo Beach 30
Buffalo 29
Wilmington 28
São Paulo 27
Amsterdam 25
Lomé 25
Chennai 24
Frankfurt am Main 22
Manchester 22
Riyadh 21
Rome 21
Tokyo 21
Madrid 20
Sindelfingen 20
Woodbridge 20
Cotonou 19
Santa Clara 19
Washington 18
Jinan 17
Mumbai 17
Monza 16
Seattle 16
Abuja 15
Bologna 15
Chicago 14
Houston 14
Nuremberg 14
Boston 13
Haiphong 13
Orem 13
Shanghai 13
Bethnal Green 11
Ghaziabad 11
Nanjing 11
Phoenix 11
Warsaw 11
Ann Arbor 10
Atlanta 10
Guangzhou 10
Liverpool 10
Montreal 9
Ankara 8
Brasília 8
Brussels 8
Dongguan 8
Islington 8
Redwood City 8
Tianjin 8
Vancouver 8
Bari 7
Chieri 7
City of London 7
Fairfield 7
Giza 7
Marseille 7
Mexico City 7
Vienna 7
Wakabadai 7
Baghdad 6
Budapest 6
Gurugram 6
Hyderabad 6
Igusa 6
Istanbul 6
Jyväskylä 6
Liège 6
Minamimotomachi 6
Poplar 6
Stockholm 6
Toronto 6
Athens 5
Barcelona 5
Belo Horizonte 5
Totale 4.952
Salva come PNG Salva come JPEG
Nome #
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 344
A systematic review of treatments for pityriasis lichenoides 329
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 258
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 194
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 171
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 170
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 169
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 166
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 160
Gender perspective in the management of psoriasis 158
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 157
A case of genital primary syphilis with superimposed impetigo 153
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 150
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 144
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 143
Amicrobial Pustulosis of the Folds: Report of Three New Cases 135
A man with a widespread bullous eruption 134
Advanced Glycation End Products and Psoriasis 134
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 130
Annular Erythema: New and Revisited Variants 130
Idiopathic lichenoid and granulomatous dermatitis 130
Adrenergic urticaria successfully treated with omalizumab 129
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 127
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 125
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 125
Clinical profile and co-infections of urethritis in males 124
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 124
Price variability of TNF-α inhibitor biosimilars among European countries 117
Biological agents targeting interleukin-13 for atopic dermatitis 115
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 113
Uncommon Non‑Infectious Annular Dermatoses 113
Atopic Dermatitis in the Elderly Population 109
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 109
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 109
Interferon-beta injection site reactions in patients with multiple sclerosis. 109
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 102
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 99
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 99
Managing the Patient with Psoriasis and Metabolic Comorbidities 98
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 98
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 97
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 97
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 91
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 91
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 90
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 89
Eosinophilic annular erythema successfully treated with cyclosporine 88
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 87
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 82
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 81
null 80
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 79
Visual Vignette 79
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 77
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 76
Pruritus as a Distinctive Feature of Type 2 Inflammation 76
Targeting IL-4 for the Treatment of Atopic Dermatitis 76
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 75
Tailored biological treatment for patients with moderate-to-severe psoriasis 73
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 70
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 69
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 68
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 67
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 67
Overview of Atopic Dermatitis in Different Ethnic Groups 65
The Combination of Dupilumab with Other Monoclonal Antibodies 64
Lymphoplasmacytic plaque effectively treated with imiquimod 60
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 58
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 57
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 55
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 53
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 51
FARMACOECONOMIA APPLICATA ALLE MALATTIE INFIAMMATORIE CRONICHE CUTANEE (PSORIASI E DERMATITE ATOPICA) 46
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study 43
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 36
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study 25
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 22
The Girl with a Pearl Earring: A dermatological puzzle 19
Klinische Merkmale und Behandlungen der transitorischen akantholytischen Dermatose (Morbus Grover): ein systematischer Review 17
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence 14
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis) 13
Real-world comparison of IL-23 inhibitors in moderate-to-severe plaque psoriasis: a focus on super responders—IL PSO (Italian landscape Psoriasis) 4
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis) 3
Real‑World Efficacy of IL‑23 Inhibitors in Psoriasis Affecting High‑Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) 3
Totale 8.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.259
article - articoli 28.662
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 130
patent - brevetti 0
selected - selezionate 0
volume - volumi 467
Totale 58.518
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 2 13 10
2021/2022228 13 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/20264.573 293 169 674 610 1.141 273 428 293 340 352 0 0
Totale 8.436